SCIENTIFIC EVIDENCE

A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated.

Acta pharmaceutica Sinica. B
Li J, Lu J, Guo H, Zhou J, Wang S, Jiang K, Chai Z, Yao S, Wang X, Lu L, Xie C, Chen Y, Lu W.

Publication Overview

Key findings, Countstar context, and access to the original paper.
2021
Cancer Research
Immunology
No items found.
Key Finding
The widely accepted peptide c(RGDyK)-modified liposome loading AL3810 of multiple dosing caused hypothermia, activated anti-c(RGDyK)-liposome IgG and IgM antibody and pertinent complements C3b and C5b-9, and experienced complement-dependent opsonization. Stemming from attenuated immunogenicity, peptide mn strengthened liposome functions as a promising nanocarrier platform for molecular targeting agents.
Countstar Connection
The study used Countstar (model not specified) for cell-count assessment in the study's cell samples during quality assessment in the 2021 Acta pharmaceutica Sinica. B study.
View paper ↗
Stay Connected toCountstar Science
Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.
Meet us online
Products
About Us
Contact
© 2026 Countstar. All rights reserved.